ProCE Banner Activity

Mapping TROP-2–Targeted ADCs Into the NSCLC Treatment Landscape

Clinical Thought

Approval of 2 new TROP-2–targeted ADCs in NSCLC is on the horizon, but how should they be sequenced with other ADCs, and should patients be concerned about key toxicities associated with these agents? 

Released: May 02, 2024

Expiration: May 01, 2025

Share

Faculty

Luis Paz-Ares

Luis Paz-Ares, MD, PhD

Chair of the Medical Oncology Department
Hospital Universitario 12 de Octubre
Associate Professor
Universidad Complutense de Madrid
Head of the Lung Cancer Unit
CNIO (Spanish National Cancer Research Center)
Madrid, Spain

David Planchard

David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

Helena Yu

Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Disclosure

Primary Author

Luis Paz-Ares, MD, PhD

Chair of the Medical Oncology Department
Hospital Universitario 12 de Octubre
Associate Professor
Universidad Complutense de Madrid
Head of the Lung Cancer Unit
CNIO (Spanish National Cancer Research Center)
Madrid, Spain

Luis Paz-Ares, MD, PhD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb, Gilead, Lilly, Merck-Serono, MSD, Novartis, Pfizer, PharmaMar, Roche, Sanofi; grant/contract: AstraZeneca, Bristol Myers Squibb, MSD, Pfizer, PharmaMar; honoraria/speakers bureau: AstraZeneca, Janssen, Merck, Mirati, Sanofi.

David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

David Planchard, MD, PhD: consultant/advisor/speaker: AbbVie, ArriVent, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Janssen, Lilly, Merck, Mirati, Novartis, Pfizer, Pierre Fabre, Roche, Seagen, Takeda.

Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Helena Yu, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Black Diamond, Blueprint, Cullinan, Daiichi Sankyo, Janssen, Taiho; researcher (paid to institution): Novartis, Pfizer.